Skip to main content

Table 1 Baseline demographic status and comorbidity compared between hypertonic solution cohort and comparison cohort

From: Early utilization of hypertonic peritoneal dialysate and subsequent risks of non-traumatic amputation among peritoneal dialysis patients: a nationwide retrospective longitudinal study

Variable PD patients p-value
  Comparison cohort HPD cohort  
  N = 296 (%) N = 203 (%)  
Age, mean (SD) years 50.9 (17.1) 56.1 (15.8) 0.0007
  30 41 (13.9) 12 (5.9) 0.0030
  31-50 107 (36.1) 59 (29.1)  
  51-70 105 (35.5) 96 (47.3)  
  >70 43 (14.5) 36 (17.7)  
Sex    0.3500
  Female 170 (57.4) 108 (53.2)  
  Male 126 (42.6) 95 (46.8)  
Comorbidity    
  Hypertension 247 (83.4) 182 (89.7) 0.0498
  Ischemic heart disease 81 (27.4) 70 (34.5) 0.0891
  Diabetes 79 (26.7) 89 (43.8) <0.0001
  DM foot ulcer 5 (1.7) 5 (2.5) 0.5445
  DM neuropathy 13 (4.4) 19 (9.4) 0.0261
  Heart failure 61 (20.6) 60 (29.6) 0.0220
  Peripheral vascular disease 5 (1.7) 5 (2.5) 0.5445
  Hyperparathyroidism 7 (2.4) 8 (3.9) 0.3111
Follow-up duration, mean (SD) 4.2 (2.9) 3.1 (2.8) <0.0001
DM duration, mean (SD) 9.8 (3.3) 9.7 (3.6) 0.8736
  1. *t-test.